Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis

Silvia Rosina1, Giulia C Varnier2, Angela Pistorio3

  • 1S. Rosina, MD, PhD, N. Ruperto, MD, MPH, UOC Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy; silviarosina85@gmail.com.

The Journal of Rheumatology
|November 16, 2020
PubMed
Abstract

Insights

New shortened Manual Muscle Test (MMT-4 and MMT-6) versions effectively assess muscle strength in juvenile dermatomyositis (JDM). These tools demonstrate strong validity and responsiveness, making them suitable for clinical practice and research.

Area of Science:

  • Rheumatology
  • Pediatrics
  • Clinical Assessment

Background:

  • Juvenile dermatomyositis (JDM) is a rare autoimmune disease causing muscle weakness.
  • Accurate muscle strength assessment is crucial for monitoring JDM progression and treatment efficacy.
  • The Manual Muscle Test-8 (MMT-8) is a comprehensive tool, but shorter versions may improve clinical utility.

Purpose of the Study:

  • To develop and validate shortened versions of the MMT-8 for use in JDM.
  • To assess the metrologic properties of these reduced tools, including validity, reliability, and responsiveness.

Main Methods:

  • Retrospective analysis of MMT-8 data from three multinational datasets.
  • Development of MMT-4 and MMT-6 based on the most frequently impaired muscle groups.
  • Evaluation of construct validity, internal consistency, discriminant ability, and responsiveness to change.

Main Results:

  • MMT-4 and MMT-6 demonstrated strong correlations with MMT-8 and other muscle strength measures.
  • Both shortened tools showed good internal consistency (0.88-0.96).
  • MMT-4 and MMT-6 effectively discriminated between disease activity states and patient satisfaction with illness course.
  • Responsiveness to change was slightly superior for MMT-4 and MMT-6 compared to MMT-8.

Conclusions:

  • MMT-4 and MMT-6 exhibit comparable metrologic performance to established muscle strength tools.
  • These shortened versions are suitable for clinical practice, research, and clinical trials in JDM.
  • Further prospective validation in diverse patient populations is recommended.